Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O94826

UPID:
TOM70_HUMAN

ALTERNATIVE NAMES:
Mitochondrial precursor proteins import receptor; Translocase of outer membrane 70 kDa subunit; Translocase of outer mitochondrial membrane protein 70

ALTERNATIVE UPACC:
O94826; D3DN48

BACKGROUND:
Mitochondrial import receptor subunit TOM70, a key player in mitochondrial biogenesis, recognizes and mediates the translocation of preproteins into mitochondria. This function is critical for maintaining mitochondrial health and energy metabolism. Additionally, TOM70 is involved in activating antiviral responses through TBK1 and IRF3 upon Sendai virus infection, highlighting its role in cellular defense mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Mitochondrial import receptor subunit TOM70 offers valuable insights into developing novel therapeutic approaches. Its critical role in mitochondrial health and antiviral defense positions it as a potential target for therapies aimed at mitochondrial diseases and enhancing antiviral immunity.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.